Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.

ABSTRACT:

Background

Anti-IL-5 might be a useful therapeutic agent for eosinophilic disorders, yet its immunologic consequences have not been well characterized.

Objective

We sought to characterize the hematologic and immunologic effects of anti-IL-5 in human subjects.

Methods

The effects of 3-month infusions of mepolizumab were assessed in 25 patients with a variety of eosinophilic syndromes. Samples with increased IL-5 levels after therapy were analyzed by using size exclusion filtration. Immunoreactive IL-5 fraction and plasma samples were subsequently precipitated with saturating concentrations of protein A/G.

Results

Twenty-three patients responded to anti-IL-5 therapy with a decrease in blood eosinophil counts and a reduced percentage of CCR3(+) cells by 20- and 13

SUBMITTER: Stein ML 

PROVIDER: S-EPMC2749495 | biostudies-literature | 2008 Jun

REPOSITORIES: biostudies-literature